CytRx Corp.

CytRx Corp.

CytRx Corp.

Overview
Date Founded

2002

Headquarters

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, 90049, USA

Type of Company

Public

Employees (Worldwide)

4

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

CytRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

Contact Data
Trying to get in touch with decision makers at CytRx Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Chief Financial Officer, Treasurer & Senior Vice President

Director

President & Chief Executive Officer

Vice President-Drug Discovery

Senior Director, Drug Discovery

Vice President, Business Development & Investor Relations

Clinical Research Study Manager

Board of Directors

Chief Executive Officer, President at Kriegsman Family Office

Director at CytRx Corp.

Professor, Molecular & Medical Pharmacology at University of California - Los Angeles

Director, President & Chief Executive Officer at Panbela Therapeutics, Inc.

Paths to CytRx Corp.
Potential Connections via
Relationship Science
You
CytRx Corp.
Recent Transactions
Details Hidden

CytRx Corp. issued USD Common Stock

Details Hidden

CytRx Corp. issued USD Common Stock

Details Hidden

CytRx Corp. issued USD Common Stock

Transaction Advisors
Auditor

Advised onCytRx Corp. issued USD Common Stock

Underwriter

Advised onCytRx Corp. issued USD Common Stock

Underwriter

Advised onCytRx Corp. issued USD Common Stock

Managing Director

Advised onCytRx Corp. issued USD Common Stock

Professional

Advised onMast Therapeutics, Inc. purchases Synthrx, Inc. from CytRx Corp.

Advisors & Consultants
Publicist

Managing Director at Argot Partners LLC

Publicist

Professional at Scient Public Relations

Publicist

Former Professional at Legend Securities, Inc.

Clients

NantWorks LLC develops technology based semiconductor and advanced networks for healthcare improvements. Its solution is for life threatening diseases such as cancer, infectious diseases and Alzheimer’s. The company was founded by Patrick Soon-Shiong in September 2011 and is headquartered in Culver City, CA.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Orphazyme A/S is a biopharmaceutical company, which engages in the development of treatment for patients living with life-threatening and debilitating rare diseases. It provides Arimoclomol program and molecular entities program. The company was founded by Anders Morkeberg Hinsby, Marja Jaattela, Martin Rahbek Kornum, and Thomas Kirkegaard Jensen in 2009 and is headquartered in Copenhagen, Denmark.

Key Stats and Financials As of 2020
Market Capitalization
$30.2M
Total Enterprise Value
$51.2M
Earnings Per Share
$-0.19
Revenue
$0
Debt TEV
0.01x
TEVNet Income
-7.65x
EBITDA
$-6.8M
Total Equity
$8.87M
Total Debt
$596K
Net Profit
$-6.7M
Three Year Compounded Annual Growth Rate Of Revenue
-100%
Investors
Details Hidden
Competitors
Seagen Inc. Pharmaceuticals - Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Roche Holding AG Pharmaceuticals - Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Takeda Pharmaceutical Co., Ltd. Pharmaceuticals - Osaka, Japan

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CytRx Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CytRx Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and CytRx Corp..